Yang Liu

Yang Liu is a cancer immunologist turned serial biotech founder who chairs and runs OncoC4, the Rockville, Maryland company developing next-generation immune checkpoint antibodies. After decades as an endowed professor at NYU, Ohio State, Michigan, and beyond, he co-founded OncoImmune (acquired by Merck for $425M) and then OncoC4, whose lead anti-CTLA-4 antibody gotistobart is in late-stage development with BioNTech. He left full-time academia to take his own discoveries from the bench into patients.